The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
5,7,3'-trihydroxy-3,4'-dimethoxyflavone affects the phosphorylation of CCNB1 protein 5,7,3'-trihydroxy-3,4'-dimethoxyflavone results in increased expression of CCNB1 protein
chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of 1-benzyl-1,4-dihydronicotinamide] which results in increased reduction of Ubiquinone Q2]; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of 1-benzyl-1,4-dihydronicotinamide] which results in increased reduction of Vitamin K 3]; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]
5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of and results in increased degradation of NFKBIA protein]
5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA]; 5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 protein]; [5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 protein]] which results in decreased abundance of Nitric Oxide
5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 mRNA]; 5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 protein]; [5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 protein]] which results in decreased abundance of Dinoprostone
CYP1A1 protein results in increased metabolism of acacetin acacetin results in increased expression of CYP1A1 mRNA acacetin results in decreased activity of CYP1A1 protein
CYP1B1 protein results in increased metabolism of acacetin acacetin results in increased expression of CYP1B1 mRNA acacetin results in decreased activity of CYP1B1 protein acacetin binds to and results in decreased activity of CYP1B1 protein
acacetin results in decreased activity of CYP3A2 protein acacetin binds to and results in decreased activity of CYP3A4 protein; acacetin inhibits the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 4-hydroxymidazolam]; acacetin promotes the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam] acacetin results in increased expression of CYP3A4 mRNA
acacetin results in increased phosphorylation of MAPK3 protein Acetylcysteine inhibits the reaction [acacetin results in increased phosphorylation of MAPK3 protein]
acacetin results in increased activity of NR1I2 protein acacetin results in increased expression of NR1I2 mRNA acacetin results in increased activity of and results in increased expression of NR1I2 protein; sulforaphane inhibits the reaction [acacetin results in increased activity of NR1I2 protein]
casticin results in decreased expression of BCL2L1 protein casticin promotes the reaction [Fluorouracil results in decreased expression of BCL2L1 protein]; Fluorouracil promotes the reaction [casticin results in decreased expression of BCL2L1 protein] casticin results in increased expression of BCL2L1 mRNA
casticin results in increased expression of BID protein casticin inhibits the reaction [Fluorouracil results in increased expression of BID protein] casticin results in decreased expression of BID protein
casticin promotes the reaction [MIR148A mRNA results in decreased expression of BMI1 mRNA]; DNMT1 protein inhibits the reaction [casticin results in decreased expression of BMI1 protein]; MIR148A mRNA promotes the reaction [casticin results in decreased expression of BMI1 mRNA]
casticin results in increased cleavage of and results in increased activity of CASP3 protein casticin inhibits the reaction [Fluorouracil results in increased activity of CASP3 protein] casticin results in increased activity of CASP3 protein
casticin results in increased cleavage of and results in increased activity of CASP8 protein; casticin results in increased expression of and results in increased activity of CASP8 protein
casticin results in increased cleavage of and results in increased activity of CASP9 protein casticin promotes the reaction [Fluorouracil results in increased activity of CASP9 protein] casticin results in increased activity of CASP9 protein
casticin results in decreased expression of CD44 mRNA; casticin results in decreased expression of CD44 protein casticin affects the reaction [MIR148A mRNA affects the expression of CD44 mRNA]; casticin promotes the reaction [MIR148A mRNA results in decreased expression of CD44 protein]; DNMT1 protein inhibits the reaction [casticin results in decreased expression of CD44 protein]; MIR148A mRNA promotes the reaction [casticin results in decreased expression of CD44 protein]
casticin affects the reaction [MIR148A mRNA affects the activity of DNMT1 protein]; casticin affects the reaction [MIR148A mRNA affects the expression of DNMT1 mRNA]; casticin promotes the reaction [MIR148A mRNA results in decreased activity of DNMT1 protein]; casticin results in decreased expression of and results in decreased activity of DNMT1 protein; DNMT1 protein inhibits the reaction [casticin results in decreased activity of DNMT1 protein]; DNMT1 protein inhibits the reaction [casticin results in decreased expression of BMI1 protein]; DNMT1 protein inhibits the reaction [casticin results in decreased expression of CD44 protein]; DNMT1 protein inhibits the reaction [casticin results in decreased expression of EPCAM protein]; DNMT1 protein inhibits the reaction [casticin results in decreased expression of NANOG protein]; DNMT1 protein inhibits the reaction [casticin results in decreased expression of POU5F1 protein]; DNMT1 protein inhibits the reaction [casticin results in increased expression of MIR148A mRNA]; MIR148A mRNA affects the reaction [casticin results in decreased activity of DNMT1 protein]; MIR148A mRNA affects the reaction [casticin results in decreased expression of DNMT1 mRNA]; MIR148A mRNA promotes the reaction [casticin results in decreased activity of DNMT1 protein]
casticin results in decreased expression of ENDOG protein casticin results in increased expression of ENDOG protein casticin inhibits the reaction [Fluorouracil results in increased expression of ENDOG protein]
casticin promotes the reaction [MIR148A mRNA results in decreased expression of EPCAM mRNA]; DNMT1 protein inhibits the reaction [casticin results in decreased expression of EPCAM protein]; MIR148A mRNA promotes the reaction [casticin results in decreased expression of EPCAM mRNA]
casticin results in increased expression of MIR148A mRNA casticin affects the reaction [MIR148A mRNA affects the activity of DNMT1 protein]; casticin affects the reaction [MIR148A mRNA affects the expression of CD44 mRNA]; casticin affects the reaction [MIR148A mRNA affects the expression of DNMT1 mRNA]; casticin affects the reaction [MIR148A mRNA results in increased expression of MIR148A mRNA]; casticin promotes the reaction [MIR148A mRNA results in decreased activity of DNMT1 protein]; casticin promotes the reaction [MIR148A mRNA results in decreased expression of BMI1 mRNA]; casticin promotes the reaction [MIR148A mRNA results in decreased expression of CD44 protein]; casticin promotes the reaction [MIR148A mRNA results in decreased expression of EPCAM mRNA]; casticin promotes the reaction [MIR148A mRNA results in decreased expression of NANOG mRNA]; casticin promotes the reaction [MIR148A mRNA results in decreased expression of POU5F1 mRNA]; DNMT1 protein inhibits the reaction [casticin results in increased expression of MIR148A mRNA]; MIR148A mRNA affects the reaction [casticin results in decreased activity of DNMT1 protein]; MIR148A mRNA affects the reaction [casticin results in decreased expression of DNMT1 mRNA]; MIR148A mRNA affects the reaction [casticin results in increased expression of MIR148A mRNA]; MIR148A mRNA promotes the reaction [casticin results in decreased activity of DNMT1 protein]; MIR148A mRNA promotes the reaction [casticin results in decreased expression of BMI1 mRNA]; MIR148A mRNA promotes the reaction [casticin results in decreased expression of CD44 protein]; MIR148A mRNA promotes the reaction [casticin results in decreased expression of EPCAM mRNA]; MIR148A mRNA promotes the reaction [casticin results in decreased expression of NANOG mRNA]; MIR148A mRNA promotes the reaction [casticin results in decreased expression of POU5F1 mRNA]
casticin promotes the reaction [MIR148A mRNA results in decreased expression of NANOG mRNA]; DNMT1 protein inhibits the reaction [casticin results in decreased expression of NANOG protein]; MIR148A mRNA promotes the reaction [casticin results in decreased expression of NANOG mRNA]
casticin promotes the reaction [MIR148A mRNA results in decreased expression of POU5F1 mRNA]; DNMT1 protein inhibits the reaction [casticin results in decreased expression of POU5F1 protein]; MIR148A mRNA promotes the reaction [casticin results in decreased expression of POU5F1 mRNA]
casticin promotes the reaction [Fluorouracil results in increased expression of SOD1 protein]; Fluorouracil promotes the reaction [casticin results in increased expression of SOD1 protein]
5,7-dimethoxyflavone inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; 5,7-dimethoxyflavone inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]; 5,7-dimethoxyflavone inhibits the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]]
5,7-dimethoxyflavone inhibits the reaction [Diethylnitrosamine results in increased expression of CCND1 mRNA]; 5,7-dimethoxyflavone inhibits the reaction [Diethylnitrosamine results in increased expression of CCND1 protein]
5,7-dimethoxyflavone inhibits the reaction [Diethylnitrosamine results in increased expression of CSNK2B mRNA]; 5,7-dimethoxyflavone inhibits the reaction [Diethylnitrosamine results in increased expression of CSNK2B protein]
5,7-dimethoxyflavone inhibits the reaction [Diethylnitrosamine affects the localization of CTNNB1 protein modified form]; 5,7-dimethoxyflavone inhibits the reaction [Diethylnitrosamine results in increased expression of CTNNB1 mRNA]
5,7-dimethoxyflavone inhibits the reaction [Benzo(a)pyrene results in increased expression of and results in increased activity of CYP1A1 protein]; 5,7-dimethoxyflavone inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]; 5,7-dimethoxyflavone inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein] 5,7-dimethoxyflavone results in decreased activity of CYP1A1 protein
5,7-dimethoxyflavone inhibits the reaction [Benzo(a)pyrene results in increased activity of CYP1B1 protein]; 5,7-dimethoxyflavone inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA]; 5,7-dimethoxyflavone inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 protein] 5,7-dimethoxyflavone results in decreased activity of CYP1B1 protein
5,7-dimethoxyflavone inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]; 5,7-dimethoxyflavone inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein]; 5,7-dimethoxyflavone inhibits the reaction [IL1B protein results in increased secretion of IL6 protein]
5,7-dimethoxyflavone inhibits the reaction [Diethylnitrosamine results in increased expression of PTGS2 mRNA]; 5,7-dimethoxyflavone inhibits the reaction [Diethylnitrosamine results in increased expression of PTGS2 protein]
5,7-dimethoxyflavone inhibits the reaction [Diethylnitrosamine results in increased expression of RELA mRNA]; 5,7-dimethoxyflavone inhibits the reaction [Diethylnitrosamine results in increased expression of RELA protein modified form]
[5,7-dimethoxyflavone co-treated with Diethylnitrosamine] results in increased expression of TP53 mRNA; [5,7-dimethoxyflavone co-treated with Diethylnitrosamine] results in increased expression of TP53 protein
cirsiliol results in decreased activity of CYP1A1 protein CYP1A1 protein results in increased metabolism of cirsiliol cirsiliol results in increased expression of CYP1A1 mRNA
cirsiliol results in increased expression of CYP1B1 mRNA CYP1B1 protein results in increased metabolism of cirsiliol cirsiliol results in decreased activity of CYP1B1 protein
diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP1 protein modified form]
diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]; KEAP1 protein inhibits the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]]; NFE2L2 protein promotes the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]]
diosmetin results in decreased activity of CYP1A1 protein CYP1A1 protein results in increased susceptibility to diosmetin [CYP1A1 protein results in increased susceptibility to Luteolin] which results in decreased abundance of diosmetin
diosmetin results in decreased activity of CYP1A2 protein [CYP1A2 protein results in increased susceptibility to Luteolin] which results in decreased abundance of diosmetin CYP1A2 protein results in increased susceptibility to diosmetin
diosmetin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; diosmetin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 4-hydroxymidazolam]
diosmetin promotes the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of HMOX1 protein]; diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of HMOX1 mRNA]; diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of HMOX1 protein]
diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of IL18 protein]; diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of IL18 protein]
diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of IL1B protein]; diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of IL1B protein]
diosmetin promotes the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of KEAP1 protein]; diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of KEAP1 protein]; KEAP1 protein inhibits the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]]; KEAP1 protein inhibits the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PARP1 protein modified form]]; KEAP1 protein inhibits the reaction [diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of KEAP1 protein]]; KEAP1 protein inhibits the reaction [diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of and affects the localization of NFE2L2 protein]]; NFE2L2 protein promotes the reaction [diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of KEAP1 protein]]
diosmetin promotes the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of NFE2L2 protein]; diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of and affects the localization of NFE2L2 protein]; KEAP1 protein inhibits the reaction [diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of and affects the localization of NFE2L2 protein]]; NFE2L2 protein promotes the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]]; NFE2L2 protein promotes the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PARP1 protein modified form]]; NFE2L2 protein promotes the reaction [diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of KEAP1 protein]]; NFE2L2 protein promotes the reaction [diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of and affects the localization of NFE2L2 protein]]
diosmetin promotes the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of NQO1 protein]; diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of NQO1 mRNA]; diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of NQO1 protein]
diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PARP1 protein modified form]; KEAP1 protein inhibits the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PARP1 protein modified form]]; NFE2L2 protein promotes the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PARP1 protein modified form]]
[Diosmin co-treated with Lipopolysaccharides] results in increased expression of BCL2 protein Diosmin inhibits the reaction [Benzo(a)pyrene results in decreased expression of BCL2 protein]
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased activity of CASP3 protein]; Diosmin inhibits the reaction [Acetic Acid results in increased expression of CASP3 protein]; Diosmin inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein] Diosmin inhibits the reaction [Benzo(a)pyrene results in increased cleavage of CASP3 protein]
Diosmin inhibits the reaction [2-Acetylaminofluorene results in decreased expression of CAT protein]; Diosmin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]
Diosmin inhibits the reaction [2-Acetylaminofluorene results in decreased expression of GSR protein] Diosmin inhibits the reaction [Benzo(a)pyrene results in decreased expression of GSR protein]
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased expression of MKI67 protein]; Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of MKI67 protein]
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased expression of PCNA protein]; Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of PCNA protein]
Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of PTGS2 protein]; Diosmin inhibits the reaction [Acetic Acid results in increased expression of PTGS2 protein] Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of PTGS2 protein]
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased expression of TNF protein]; Diosmin inhibits the reaction [Acetic Acid results in increased expression of TNF protein]; Diosmin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased activity of XDH protein] Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of XDH protein]
[[eupatilin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [eupatilin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam
eupatilin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased phosphorylation of and results in increased degradation of NFKBIA protein]
eupatilin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of NOS2 mRNA]; eupatilin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of NOS2 protein]
eupatilin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of PTGS2 mRNA]; eupatilin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of PTGS2 protein]
CYP1A1 protein results in increased susceptibility to eupatorin CYP1A1 protein results in increased metabolism of eupatorin analog eupatorin analog results in decreased activity of CYP1A1 protein eupatorin results in increased expression of CYP1A1 mRNA
CYP1B1 protein results in increased metabolism of eupatorin analog eupatorin results in increased expression of CYP1B1 mRNA eupatorin results in decreased activity of CYP1B1 protein
genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of and results in increased activity of CASP3 protein]; TLR4 protein inhibits the reaction [genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of and results in increased activity of CASP3 protein]]
CYP1B1 protein results in increased metabolism of genkwanin [CYP1B1 protein results in increased metabolism of genkwanin] which results in increased chemical synthesis of Apigenin
genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL1B mRNA]; genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased secretion of IL1B protein]; TLR4 protein inhibits the reaction [genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased secretion of IL1B protein]]
genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 mRNA]; genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased secretion of IL6 protein]; TLR4 protein inhibits the reaction [genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased secretion of IL6 protein]]
genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of MYD88 protein]; TLR4 protein inhibits the reaction [genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of MYD88 protein]]
genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of NLRP3 protein]; TLR4 protein inhibits the reaction [genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of NLRP3 protein]]
genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of PTGS2 protein]; TLR4 protein inhibits the reaction [genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of PTGS2 protein]]
genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TLR4 protein]; TLR4 protein inhibits the reaction [genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of and results in increased activity of CASP3 protein]]; TLR4 protein inhibits the reaction [genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of MYD88 protein]]; TLR4 protein inhibits the reaction [genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of NLRP3 protein]]; TLR4 protein inhibits the reaction [genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of PTGS2 protein]]; TLR4 protein inhibits the reaction [genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased secretion of IL1B protein]]; TLR4 protein inhibits the reaction [genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased secretion of IL6 protein]]; TLR4 protein inhibits the reaction [genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased secretion of TNF protein]]
genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF mRNA]; genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased secretion of TNF protein]; TLR4 protein inhibits the reaction [genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased secretion of TNF protein]]
ginkgetin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BAX protein] ginkgetin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of BAX protein]
ginkgetin inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 protein] ginkgetin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BCL2 protein]
hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of ADIPOQ mRNA]; hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of ADIPOQ protein]
hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of CEBPA mRNA]
hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of ADIPOQ mRNA]; hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of ADIPOQ protein]; hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of CEBPA mRNA]; hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of PPARG mRNA]; hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of PPARG protein]
hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of PPARG mRNA]; hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of PPARG protein]
hispidulin results in decreased activity of SLCO1B1 protein [hispidulin results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Bosentan; [hispidulin results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Methotrexate
ABCB1 protein results in increased transport of 3-methylquercetin 3-methylquercetin results in increased activity of ABCB1 protein 3-methylquercetin inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]; 3-methylquercetin promotes the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]]; 3-methylquercetin promotes the reaction [Quercetin results in increased activity of ABCB1 protein] 3-methylquercetin results in decreased expression of ABCB1 protein 3-methylquercetin results in increased expression of ABCB1 mRNA
3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] 3-methylquercetin inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]
3-methylquercetin results in decreased phosphorylation of AKT1 protein 3-methylquercetin affects the reaction [Hydrogen Peroxide results in increased phosphorylation of AKT1 protein]
3-methylquercetin results in decreased expression of CASP3 protein 3-methylquercetin inhibits the reaction [Hydrogen Peroxide results in increased activity of CASP3 protein] 3-methylquercetin results in increased activity of CASP3 protein
3-methylquercetin inhibits the reaction [Hydrogen Peroxide results in decreased activity of CAT protein]; [quercetin 3-O-glucuronide co-treated with 3-methylquercetin co-treated with Quercetin] results in increased expression of CAT mRNA; [quercetin 3-O-glucuronide co-treated with 3-methylquercetin co-treated with Quercetin] results in increased expression of CAT protein
3-methylquercetin inhibits the reaction [Benzo(a)pyrene results in increased activity of CYP1A1 protein]; [Quercetin co-treated with kaempferol co-treated with 3-methylquercetin co-treated with ginkgolide A co-treated with ginkgolide B co-treated with ginkgolide C co-treated with ginkgolide J co-treated with bilobalide] affects the activity of CYP1A1 protein; [Quercetin co-treated with kaempferol co-treated with 3-methylquercetin co-treated with ginkgolide A co-treated with ginkgolide B co-treated with ginkgolide C co-treated with ginkgolide J co-treated with bilobalide] inhibits the reaction [Benzo(a)pyrene results in increased activity of CYP1A1 protein]; [Quercetin co-treated with kaempferol co-treated with 3-methylquercetin co-treated with ginkgolide A co-treated with ginkgolide B co-treated with ginkgolide C co-treated with ginkgolide J co-treated with bilobalide] inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; [Quercetin co-treated with kaempferol co-treated with 3-methylquercetin] affects the activity of CYP1A1 protein; [Quercetin co-treated with kaempferol co-treated with 3-methylquercetin] inhibits the reaction [Benzo(a)pyrene results in increased activity of CYP1A1 protein]; [Quercetin co-treated with kaempferol co-treated with 3-methylquercetin] inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]
3-methylquercetin inhibits the reaction [EDN1 protein results in increased expression of NCF1 mRNA]; 3-methylquercetin inhibits the reaction [EDN1 protein results in increased expression of NCF1 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein]; [3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein; dorsomorphin inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein]; rottlerin inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein] [quercetin 3-O-glucuronide co-treated with 3-methylquercetin co-treated with Quercetin] results in increased expression of GCLC mRNA; [quercetin 3-O-glucuronide co-treated with 3-methylquercetin co-treated with Quercetin] results in increased expression of GCLC protein 3-methylquercetin results in increased expression of GCLC mRNA; 3-methylquercetin results in increased expression of GCLC protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein]; [3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein; dorsomorphin inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein]; rottlerin inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein] [quercetin 3-O-glucuronide co-treated with 3-methylquercetin co-treated with Quercetin] results in increased expression of HMOX1 mRNA; [quercetin 3-O-glucuronide co-treated with 3-methylquercetin co-treated with Quercetin] results in increased expression of HMOX1 protein 3-methylquercetin results in increased expression of HMOX1 mRNA; 3-methylquercetin results in increased expression of HMOX1 protein 3-methylquercetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of HMOX1 mRNA]; [3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein
3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of IL1B protein] 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL1B protein]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; [3-methylquercetin co-treated with Lipopolysaccharides] affects the expression of IL1B mRNA
3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of IL6 protein] 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL6 protein]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; [3-methylquercetin co-treated with Lipopolysaccharides] affects the expression of IL6 mRNA
3-methylquercetin inhibits the reaction [AGT protein results in increased expression of NCF1 protein]; 3-methylquercetin inhibits the reaction [EDN1 protein results in increased expression of NCF1 mRNA]; 3-methylquercetin inhibits the reaction [EDN1 protein results in increased expression of NCF1 protein]
NFE2L2 protein affects the susceptibility to 3-methylquercetin 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein]; 3-methylquercetin affects the localization of and results in increased phosphorylation of and results in increased activity of NFE2L2 protein; [3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased abundance of Glutathione; [3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein; [3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein; [3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of NQO1 mRNA; [3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of SESN2 mRNA; dorsomorphin inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein]; dorsomorphin inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]]; NFE2L2 protein affects the reaction [3-methylquercetin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]]; rottlerin inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein]; rottlerin inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein] 3-methylquercetin affects the localization of NFE2L2 protein [3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein; [3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein; NFE2L2 protein affects the reaction [3-methylquercetin results in decreased susceptibility to tert-Butylhydroperoxide]
3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased degradation of NFKBIA protein]
3-methylquercetin inhibits the reaction [[Lipopolysaccharides results in increased expression of and results in increased activity of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased activity of NOS2 protein]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; [3-methylquercetin co-treated with Lipopolysaccharides] affects the expression of NOS2 mRNA
2-chloro-5-nitrobenzanilide inhibits the reaction [3-methylquercetin results in increased activity of PPARG protein]; 3-methylquercetin binds to and results in increased activity of PPARG protein 3-methylquercetin results in increased expression of PPARG protein
3-methylquercetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of PTGS2 mRNA]; 3-methylquercetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of PTGS2 protein]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; 3-methylquercetin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein]; Acetylcysteine promotes the reaction [3-methylquercetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of PTGS2 protein]]; tin protoporphyrin IX inhibits the reaction [3-methylquercetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of PTGS2 protein]] 3-methylquercetin results in decreased activity of PTGS2 protein 3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of PTGS2 protein]
3-methylquercetin inhibits the reaction [Lipopolysaccharides affects the localization of and results in increased activity of RELA protein]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]
3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 protein]; NFE2L2 protein affects the reaction [3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]] 3-methylquercetin inhibits the reaction [Carbon Tetrachloride results in increased expression of SERPINE1 protein]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 protein]
[3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of SESN2 mRNA
3-methylquercetin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]; NFE2L2 protein affects the reaction [3-methylquercetin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]]
3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 protein]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]; NFE2L2 protein affects the reaction [3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]]; NFE2L2 protein affects the reaction [3-methylquercetin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]]
3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of TNF protein] 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of TNF protein]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
jaceosidin results in decreased expression of CFLAR mRNA; jaceosidin results in decreased expression of CFLAR protein CFLAR protein inhibits the reaction [jaceosidin results in increased cleavage of PARP1 protein]; RELA protein inhibits the reaction [jaceosidin results in decreased expression of CFLAR protein]; SP1 protein inhibits the reaction [jaceosidin results in decreased expression of CFLAR protein]
jaceosidin results in decreased expression of MCL1 mRNA; jaceosidin results in decreased expression of MCL1 protein MCL1 protein inhibits the reaction [jaceosidin results in increased cleavage of PARP1 protein]; RELA protein inhibits the reaction [jaceosidin results in decreased expression of MCL1 protein]; SP1 protein inhibits the reaction [jaceosidin results in decreased expression of MCL1 protein]
jaceosidin results in increased cleavage of PARP1 protein benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [jaceosidin results in increased cleavage of PARP1 protein]; CFLAR protein inhibits the reaction [jaceosidin results in increased cleavage of PARP1 protein]; MCL1 protein inhibits the reaction [jaceosidin results in increased cleavage of PARP1 protein]
RELA protein inhibits the reaction [jaceosidin results in decreased expression of CFLAR protein]; RELA protein inhibits the reaction [jaceosidin results in decreased expression of MCL1 protein]
SP1 protein inhibits the reaction [jaceosidin results in decreased expression of CFLAR protein]; SP1 protein inhibits the reaction [jaceosidin results in decreased expression of MCL1 protein]
kaempferide inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; kaempferide inhibits the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]]
nobiletin inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; nobiletin promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; nobiletin promotes the reaction [ABCB1 protein results in increased import of Daunorubicin]
nobiletin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; nobiletin promotes the reaction [ABCC1 protein results in increased import of fluorexon]
[nobiletin co-treated with Hydrogen Peroxide] results in increased phosphorylation of AKT1 protein [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of AKT1 mRNA; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of and results in decreased phosphorylation of AKT1 protein
nobiletin inhibits the reaction [Hydrogen Peroxide results in increased expression of BAX protein] nobiletin inhibits the reaction [Arsenic results in increased expression of BAX protein]
nobiletin inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein] nobiletin inhibits the reaction [Arsenic results in decreased expression of BCL2 protein]
AGN 193109 inhibits the reaction [nobiletin results in decreased expression of and results in increased cleavage of CASP3 protein]; nobiletin results in decreased expression of and results in increased cleavage of CASP3 protein nobiletin inhibits the reaction [Arsenic results in increased expression of CASP3 protein]
AGN 193109 inhibits the reaction [nobiletin results in decreased expression of and results in increased cleavage of CASP9 protein]; nobiletin results in decreased expression of and results in increased cleavage of CASP9 protein nobiletin inhibits the reaction [Arsenic results in increased expression of CASP9 protein]
CYP1A1 protein results in increased metabolism of nobiletin nobiletin results in increased expression of CYP1A1 protein nobiletin inhibits the reaction [DDT results in increased expression of CYP1A1 mRNA]; nobiletin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]
nobiletin results in increased activity of CYP3A4 protein [[nobiletin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [nobiletin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of and results in decreased phosphorylation of EGFR protein; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of EGFR mRNA
nobiletin inhibits the reaction [Acetaminophen results in increased expression of GPT protein]; nobiletin inhibits the reaction [Arsenic results in increased expression of GPT protein]
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of IL1B protein; nobiletin inhibits the reaction [Acetaminophen results in increased expression of IL1B protein]; nobiletin inhibits the reaction [Arsenic results in increased expression of IL1B protein]
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of IL6 protein; nobiletin inhibits the reaction [Acetaminophen results in increased expression of IL6 protein]; nobiletin inhibits the reaction [Arsenic results in increased expression of IL6 protein]
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] affects the secretion of MMP9 protein
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of and results in decreased phosphorylation of MTOR protein; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of MTOR mRNA
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of MUC5AC mRNA; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of MUC5AC protein
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of MUC5B mRNA
AGN 193109 inhibits the reaction [nobiletin results in decreased expression of and results in increased cleavage of PARP1 protein]; nobiletin results in decreased expression of and results in increased cleavage of PARP1 protein
AGN 193109 inhibits the reaction [nobiletin results in increased expression of RARB protein] nobiletin results in increased expression of RARB mRNA; nobiletin results in increased expression of RARB protein
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] affects the secretion of TIMP1 protein
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of TNF protein; nobiletin inhibits the reaction [Acetaminophen results in increased expression of TNF protein]; nobiletin inhibits the reaction [Arsenic results in increased expression of TNF protein]
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one results in decreased expression of ABCB1 mRNA 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one results in decreased activity of ABCB1 protein 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one results in decreased expression of and results in decreased activity of ABCB1 protein; diacetyldiphenylurea bisguanylhydrazone inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one results in decreased expression of ABCB1 mRNA]
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [ABCG2 protein results in increased uptake of lucifer yellow] 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one results in decreased activity of ABCG2 protein
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one results in increased expression of CHEK2 protein modified form diacetyldiphenylurea bisguanylhydrazone inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one results in increased expression of CHEK2 protein modified form]
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one promotes the reaction [Lipopolysaccharides results in increased expression of ECE1 mRNA]; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one promotes the reaction [Lipopolysaccharides results in increased expression of ECE1 protein]
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one promotes the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of EDN1 protein]; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one promotes the reaction [Lipopolysaccharides results in increased expression of EDN1 mRNA]; [cyclo(Trp-Asp-Pro-Val-Leu) co-treated with BQ 788] inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one promotes the reaction [Lipopolysaccharides results in increased expression of EDN1 protein]]
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased expression of FASN protein]; HIF1A protein inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased expression of FASN protein]]
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased activity of GPT protein]; HIF1A protein inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased activity of GPT protein]]
HIF1A protein inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in decreased expression of PPARA protein]]; HIF1A protein inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased activity of GPT protein]]; HIF1A protein inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased expression of CXCL15 protein]]; HIF1A protein inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased expression of FASN protein]]; HIF1A protein inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased expression of IL6 protein]]; HIF1A protein inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased expression of SREBF1 protein]]; HIF1A protein inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased expression of TNF protein]] 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased expression of and affects the localization of HIF1A protein]; HIF1A protein inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in decreased expression of PPARA protein]]; HIF1A protein inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased expression of FASN protein]]; HIF1A protein inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased expression of SCD protein]]; HIF1A protein inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased expression of SREBF1 protein]]
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one analog inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one analog inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA] 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [endotoxin, Escherichia coli results in increased expression of IL1B protein]
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one analog inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one analog inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased expression of IL6 protein]; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; HIF1A protein inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased expression of IL6 protein]] 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [endotoxin, Escherichia coli results in increased expression of IL6 protein]
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one results in decreased phosphorylation of MAPK1 protein 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK1 protein]
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK3 protein] 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one results in decreased phosphorylation of MAPK3 protein
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one results in decreased expression of MMP2 mRNA; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one results in decreased expression of MMP2 protein
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one results in decreased expression of MMP9 mRNA; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one results in decreased expression of MMP9 protein 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of and results in increased activity of MMP9 protein]
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one analog inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased degradation of NFKBIA protein]
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one analog inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide]; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one analog inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one analog inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Lipopolysaccharides results in decreased expression of NOS2 protein]; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in decreased expression of PPARA protein]; HIF1A protein inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in decreased expression of PPARA protein]]
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one analog inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone]; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one analog inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one analog inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one analog inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein] 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein]
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Lipopolysaccharides results in decreased expression of and results in decreased activity of RHOA protein]
[5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one co-treated with Lipopolysaccharides] results in increased phosphorylation of ROCK2 protein; [cyclo(Trp-Asp-Pro-Val-Leu) co-treated with BQ 788] inhibits the reaction [[5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one co-treated with Lipopolysaccharides] results in increased phosphorylation of ROCK2 protein]
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased expression of SCD protein]; HIF1A protein inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased expression of SCD protein]]
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one results in decreased activity of SLC22A6 protein 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate] 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one results in decreased activity of SLC22A8 protein
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased expression of SREBF1 protein]; HIF1A protein inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased expression of SREBF1 protein]]
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one analog inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased expression of TNF protein]; HIF1A protein inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased expression of TNF protein]] 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [endotoxin, Escherichia coli results in increased expression of TNF protein]
diacetyldiphenylurea bisguanylhydrazone inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one results in increased expression of TP53 protein modified form]
pectolinarigenin results in increased phosphorylation of ATM protein TOP2A protein affects the reaction [pectolinarigenin results in increased phosphorylation of ATM protein]
pectolinarigenin results in increased expression of H2AX protein TOP2A protein affects the reaction [pectolinarigenin results in increased expression of H2AX protein]
Chloroquine promotes the reaction [pectolinarigenin results in increased lipidation of MAP1LC3B protein]; pectolinarigenin promotes the reaction [Chloroquine results in increased lipidation of MAP1LC3B protein]; TOP2A protein affects the reaction [pectolinarigenin results in increased lipidation of MAP1LC3B protein]
pectolinarigenin results in increased expression of SQSTM1 protein Chloroquine promotes the reaction [pectolinarigenin results in increased expression of SQSTM1 protein]; pectolinarigenin promotes the reaction [Chloroquine results in increased expression of SQSTM1 protein]
pectolinarigenin binds to and results in increased expression of TOP2A protein; TOP2A protein affects the reaction [pectolinarigenin results in increased expression of CDKN1A protein]; TOP2A protein affects the reaction [pectolinarigenin results in increased expression of H2AX protein]; TOP2A protein affects the reaction [pectolinarigenin results in increased expression of TP53 protein]; TOP2A protein affects the reaction [pectolinarigenin results in increased lipidation of MAP1LC3B protein]; TOP2A protein affects the reaction [pectolinarigenin results in increased phosphorylation of ATM protein]
pectolinarigenin results in increased expression of TP53 protein TOP2A protein affects the reaction [pectolinarigenin results in increased expression of TP53 protein]
sciadopitysin results in decreased activity of ABCB1 protein sciadopitysin inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]
sciadopitysin results in increased expression of BGLAP protein sciadopitysin inhibits the reaction [Antimycin A results in increased expression of BGLAP protein]
sinensetin analog inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; sinensetin inhibits the reaction [ABCB1 protein results in increased transport of Digoxin] sinensetin analog results in decreased activity of ABCB1 protein; sinensetin results in decreased activity of ABCB1 protein
sinensetin analog results in increased activity of CYP3A4 protein; sinensetin results in increased activity of CYP3A4 protein [[sinensetin analog results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [[sinensetin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [sinensetin analog results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam; [sinensetin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam
sinensetin results in decreased activity of SLCO1B1 protein [sinensetin results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Bosentan
tangeretin results in decreased activity of ABCB1 protein tangeretin inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; tangeretin inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]; tangeretin inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; tangeretin inhibits the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]]; Verapamil inhibits the reaction [tangeretin results in increased activity of ABCB1 protein] tangeretin results in decreased expression of ABCB1 protein
tangeretin inhibits the reaction [Cisplatin results in increased expression of CASP3 protein] AGN 193109 inhibits the reaction [tangeretin results in decreased expression of and results in increased cleavage of CASP3 protein]; tangeretin results in decreased expression of and results in increased cleavage of CASP3 protein
AGN 193109 inhibits the reaction [tangeretin results in decreased expression of and results in increased cleavage of CASP9 protein]; tangeretin results in decreased expression of and results in increased cleavage of CASP9 protein
tangeretin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; tangeretin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein] CYP1A1 protein results in increased metabolism of tangeretin tangeretin results in increased expression of CYP1A1 protein
tangeretin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A2 mRNA] CYP1A2 protein results in increased metabolism of tangeretin
tangeretin results in increased activity of CYP3A4 protein [[tangeretin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [tangeretin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam
tangeretin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of HMOX1 mRNA]; tangeretin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of HMOX1 protein] tangeretin metabolite results in increased expression of HMOX1 mRNA; tangeretin metabolite results in increased expression of HMOX1 protein; tangeretin results in increased expression of HMOX1 mRNA; tangeretin results in increased expression of HMOX1 protein
tangeretin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of KEAP1 mRNA]; tangeretin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of KEAP1 protein]
tangeretin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of NFE2L2 mRNA]; tangeretin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of NFE2L2 protein]; tangeretin inhibits the reaction [Cisplatin results in increased expression of NFE2L2 protein] tangeretin metabolite results in increased expression of NFE2L2 mRNA; tangeretin metabolite results in increased expression of NFE2L2 protein; tangeretin results in increased expression of NFE2L2 mRNA; tangeretin results in increased expression of NFE2L2 protein tangeretin metabolite results in decreased methylation of NFE2L2 promoter; tangeretin results in decreased methylation of NFE2L2 promoter
tangeretin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of NOS2 protein]; tangeretin inhibits the reaction [Cisplatin results in increased expression of NOS2 protein]
tangeretin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of NQO1 mRNA]; tangeretin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of NQO1 protein] tangeretin metabolite results in increased expression of NQO1 mRNA; tangeretin metabolite results in increased expression of NQO1 protein; tangeretin results in increased expression of NQO1 mRNA; tangeretin results in increased expression of NQO1 protein
AGN 193109 inhibits the reaction [tangeretin results in decreased expression of and results in increased cleavage of PARP1 protein]; tangeretin results in decreased expression of and results in increased cleavage of PARP1 protein
tangeretin results in increased expression of RARB mRNA; tangeretin results in increased expression of RARB protein AGN 193109 inhibits the reaction [tangeretin results in increased expression of RARB protein]
tangeretin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of RELA mRNA]; tangeretin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of RELA protein]; tangeretin inhibits the reaction [Cisplatin results in increased expression of RELA protein]
tangeretin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TNF mRNA]; tangeretin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TNF protein]; tangeretin inhibits the reaction [Cisplatin results in increased expression of TNF protein]
tangeretin metabolite results in increased expression of UGT1A1 mRNA; tangeretin metabolite results in increased expression of UGT1A1 protein; tangeretin results in increased expression of UGT1A1 mRNA; tangeretin results in increased expression of UGT1A1 protein
[tectochrysin results in decreased activity of ABCB1 protein] which results in decreased export of calcein AM; tectochrysin inhibits the reaction [ABCB1 protein results in decreased susceptibility to Docetaxel]; tectochrysin inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel]; tectochrysin inhibits the reaction [ABCB1 protein results in decreased susceptibility to Vincristine] ABCB1 protein results in decreased susceptibility to tectochrysin
wogonin inhibits the reaction [Ovalbumin results in increased expression of and results in increased phosphorylation of AKT1 protein] wogonin results in decreased expression of AKT1 mRNA wogonin results in decreased phosphorylation of AKT1 protein
wogonin results in increased activity of CASP3 protein wogonin results in increased expression of CASP3 mRNA wogonin inhibits the reaction [Cisplatin results in increased expression of and results in increased activity of CASP3 protein] wogonin inhibits the reaction [Bisphenol A-Glycidyl Methacrylate results in increased activity of CASP3 protein] [wogonin co-treated with Fluorouracil] results in increased activity of CASP3 protein
wogonin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in decreased activity of CAT protein] wogonin inhibits the reaction [Cisplatin results in decreased activity of CAT protein]
wogonin inhibits the reaction [Anisomycin results in increased phosphorylation of CAV1 protein]; wogonin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of CAV1 protein]
wogonin results in decreased expression of CTNNB1 protein Lithium Chloride inhibits the reaction [wogonin results in decreased expression of CTNNB1 protein]; wogonin inhibits the reaction [Cisplatin results in increased expression of CTNNB1 protein] wogonin results in increased expression of CTNNB1 protein modified form
wogonin affects the reaction [Benzo(a)pyrene affects the activity of CYP1A1 protein]; wogonin inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]; wogonin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; wogonin results in decreased expression of and results in decreased activity of CYP1A1 protein wogonin results in decreased expression of CYP1A1 mRNA
wogonin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Dinoprostone]; wogonin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; wogonin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; wogonin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 protein]; wogonin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of PTGS2 mRNA]; wogonin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of PTGS2 protein]; wogonin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased phosphorylation of MAP2K1 protein]; wogonin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased phosphorylation of MAP2K2 protein]; wogonin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased phosphorylation of MAPK1 protein]; wogonin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased phosphorylation of MAPK3 protein]; wogonin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased phosphorylation of MAPK8 protein]; wogonin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased phosphorylation of MAPK9 protein]; wogonin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased phosphorylation of RELA protein]; wogonin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased phosphorylation of SRC protein]
wogonin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL1B protein] wogonin inhibits the reaction [Cisplatin results in increased expression of IL1B protein]
wogonin results in increased expression of IL6 protein wogonin results in increased secretion of IL6 protein wogonin results in increased expression of IL6 mRNA; wogonin results in increased expression of IL6 protein
wogonin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of JUN protein]; wogonin inhibits the reaction [lipoteichoic acid results in increased phosphorylation of JUN protein] wogonin results in decreased expression of JUN mRNA
wogonin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK1 protein] wogonin affects the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK1 protein]; wogonin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased phosphorylation of MAPK1 protein] wogonin results in decreased phosphorylation of MAPK1 protein
wogonin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK3 protein] wogonin affects the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK3 protein]; wogonin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased phosphorylation of MAPK3 protein] wogonin results in decreased phosphorylation of MAPK3 protein
wogonin inhibits the reaction [[Lipopolysaccharides co-treated with Tetradecanoylphorbol Acetate] results in increased activity of MMP9 protein] wogonin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of and results in increased activity of MMP9 protein]; wogonin results in decreased expression of and results in decreased activity of MMP9 protein
wogonin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; wogonin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 protein]; wogonin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 protein]; wogonin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; wogonin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; wogonin inhibits the reaction [lipoteichoic acid results in increased expression of NOS2 mRNA]; wogonin inhibits the reaction [lipoteichoic acid results in increased expression of NOS2 protein] wogonin inhibits the reaction [[Lipopolysaccharides co-treated with Tetradecanoylphorbol Acetate] results in increased expression of NOS2 protein]
wogonin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of PTGS2 mRNA]; wogonin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of PTGS2 protein]; wogonin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 protein]
wogonin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased phosphorylation of RELA protein]; wogonin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of RELA protein] wogonin results in increased phosphorylation of RELA protein wogonin inhibits the reaction [Cisplatin results in increased expression of RELA protein]
[wogonin results in decreased activity of SLC22A6 protein] which results in increased susceptibility to and results in increased activity of aristolochic acid I
wogonin results in decreased activity of SLC22A8 protein [wogonin results in decreased activity of SLC22A8 protein] which results in increased susceptibility to and results in increased activity of aristolochic acid I
wogonin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF protein]; wogonin inhibits the reaction [Ovalbumin results in increased expression of TNF protein] wogonin results in decreased expression of TNF mRNA wogonin analog results in decreased expression of TNF protein; wogonin results in decreased expression of TNF protein wogonin inhibits the reaction [Cisplatin results in increased expression of TNF protein]
browse the term
